{"id":79669,"date":"2012-09-26T07:16:30","date_gmt":"2012-09-26T07:16:30","guid":{"rendered":"http:\/\/www.immortalitymedicine.tv\/uncategorized\/bio-praises-introduction-of-the-high-technology-small-business-research-incentives-act.php"},"modified":"2024-08-17T15:56:58","modified_gmt":"2024-08-17T19:56:58","slug":"bio-praises-introduction-of-the-high-technology-small-business-research-incentives-act","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/bio-praises-introduction-of-the-high-technology-small-business-research-incentives-act.php","title":{"rendered":"BIO Praises Introduction of the High Technology Small Business Research Incentives Act"},"content":{"rendered":"<p><p>    WASHINGTON--(BUSINESS WIRE)--  <\/p>\n<p>    The Biotechnology Industry Organization (BIO) applauds Sens.    Robert Menendez (D-NJ) and Olympia Snowe (R-ME) and Reps. Jim    Gerlach (R-PA) and Richard Neal (D-MA) for introducing the High    Technology Small Business Research Incentives Act (H.R.    6559\/S.3595).  <\/p>\n<p>    Biotech companies are working every day to solve the greatest    challenges facing our society  whether its finding a cure for    cancer, protecting against bio-terror threats, or creating    renewable energy and renewable chemicals.  <\/p>\n<p>    Biotech R&D is a particularly high-risk undertaking because    of the substantial start-up costs, lengthy experimentation    period, and possibility that the technology will not prove    viable. The legislation would make it more attractive to invest    in biotech and other high tech industries.  <\/p>\n<p>    Under the proposal, biotech companies would be able to enter    into joint ventures with investors, who could then utilize the    losses and tax credits of an R&D project. The bill would    apply to entities that devote a significant percentage of their    expenses to R&D, have fewer than 250 employees, and have    less than $150 million in gross assets. It is important to note    that this legislation does not create any new tax incentives.  <\/p>\n<p>    BIOs President and CEO Jim Greenwood made the following    statement:  <\/p>\n<p>    Biotechnology is a leading force for innovation in America -    and innovation is key for our economic health and prosperity.    Today, our small companies face significant hurdles to raise    early stage capital. Every step we take to increase investment    could provide important capital for groundbreaking biotech    R&D projects.  <\/p>\n<p>    Through the tax code, Congress historically has provided    opportunities that encourage private investment in pre-revenue,    R&D-intensive companies. The early growth of the biotech    industry in the 1980s was due in part to the ability of    investors to support projects aimed at finding new cures and    treatments through similar joint ventures. This legislation    will help spur greater private investment in biotech and other    R&D intensive industries.  <\/p>\n<p>    BIO applauds the sponsors of this bill and pledges to work    with the Congress to ensure this legislation is passed.  <\/p>\n<p>    About BIO  <\/p>\n<\/p>\n<p>View post:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/bio-praises-introduction-high-technology-180700801.html;_ylt=A2KJNF_Hq2JQgHEAhtX_wgt.\" title=\"BIO Praises Introduction of the High Technology Small Business Research Incentives Act\" rel=\"noopener\">BIO Praises Introduction of the High Technology Small Business Research Incentives Act<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WASHINGTON--(BUSINESS WIRE)-- The Biotechnology Industry Organization (BIO) applauds Sens. Robert Menendez (D-NJ) and Olympia Snowe (R-ME) and Reps. Jim Gerlach (R-PA) and Richard Neal (D-MA) for introducing the High Technology Small Business Research Incentives Act (H.R <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/biotechnology\/bio-praises-introduction-of-the-high-technology-small-business-research-incentives-act.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246860],"tags":[],"class_list":["post-79669","post","type-post","status-publish","format-standard","hentry","category-biotechnology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/79669"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=79669"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/79669\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=79669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=79669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=79669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}